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Abstract
Background Chronic spontaneous urticaria (CSU) is
associated with considerable burden, but data from Euro-
pean patients are limited.
Methods This study is a retrospective, cross-sectional
analysis of National Health and Wellness Survey data from
the five largest EU countries (5EU: France, Germany, Italy,
Spain, and the UK) collected between 2010 and 2013.
Burden of disease for patients with CSU was estimated by
comparing individuals currently treated for chronic urti-
caria (proxy CSU cases) with controls selected from
respondents without chronic urticaria. Matching and
regression models were used to quantify the impact of
chronic urticaria on health-related quality of life, self-re-
ported psychological complaints, work and activity
impairment, and healthcare use.
Results The sample included 175,923 respondents.
Prevalence of diagnosed chronic urticaria was 0.5 and
0.2 % were treating the condition with a prescription.
Cases (N = 369) had substantially lower (worse) regres-
sion-adjusted mean Mental Component Summary (40.2 vs.
45.4), Physical Component Summary (44.6 vs. 49.9), and
SF-6D health utility scores (0.63 vs. 0.71; all p\ 0.001)
relative to controls (N = 1476), differences that exceed
accepted minimally important differences for these mea-
sures. Depression, anxiety, and sleep difficulties were
approximately twice as prevalent among those currently
receiving treatment for chronic urticaria (all p\ 0.001).
Cases also had elevated presenteeism (31 vs. 17 %),
overall work impairment (37 vs. 20 %), and impairment in
non-work activities (42 vs. 26 %; all p\ 0.01) relative to
controls. Physician visits (9.1 vs. 4.9), emergency room
visits (0.8 vs. 0.3), and hospitalizations (0.3 vs. 0.2) were
more frequent than in controls (all p\ 0.01).
Conclusions This research adds to the existing evidence
showing significant burden of CSU.
Key Points for Decision Makers
One in every 200 adults in the five largest countries
in the EU has been diagnosed with chronic urticaria,
and 40 % of them are currently using a prescription
treatment.
The impact on patients’ lives goes beyond effects on
skin; currently treated patients experience higher
levels of health-related impairment in their
functioning in work and non-work activities and
quality of life, and are more frequent users of
healthcare than similar individuals without the
condition.
Practitioners need to be aware of the treatment
options and find something that works for each
patient.
Electronic supplementary material The online version of this
article (doi:10.1007/s40271-015-0145-9) contains supplementary
material, which is available to authorized users.
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Chronic spontaneous urticaria (CSU) is defined as the
‘‘spontaneous appearance of wheals, angioedema or
both C6 weeks due to known and unknown causes’’ [1].
CSU often has no discernable external cause and is asso-
ciated with an underlying autoimmune mechanism, which
can be confirmed by testing for autoantibodies, in 30–50 %
of cases [2, 3]. CSU is the most common type of chronic
urticaria, accounting for approximately two-thirds of all
cases [4]. Only a few studies have examined the prevalence
of CSU in European countries, and these estimate the rate
at between 0.1 and 0.8 % in samples from Sweden, Spain,
and Germany [5–7]. The disease is most common among
patients aged 20–40 years, but all age groups can be
affected [4]. Studies also consistently show that women
suffer from this disease at almost twice the rate of men
[6–8].
The burden of CSU can be considerable. Published data
on patients with chronic urticaria, including studies specific
to CSU patients as well as studies examining chronic
urticaria without differentiating between types, indicate
that issues with fatigue, pain, and lack of sleep or insomnia
are commonly reported, often due to the constant itching
that accompanies their urticaria [9]. The visible lesions can
lead to emotional upset and withdrawal from social activ-
ities [10, 11]. Indeed, CSU can lead to psychological
complaints such as anxiety, depression, or irritability [9],
which can result in significant reductions in quality of life
among CSU patients [12]. In addition to physical and
emotional outcomes, some data indicate CSU symptoms
can carry a high socioeconomic burden through a combi-
nation of direct healthcare costs and loss of work produc-
tivity [7].
While there is some literature on the relationship
between CSU and economic and quality-of-life outcomes,
research in this area remains limited, including few
studies conducted among Europeans with the condition.
Previous research characterizing the condition has drawn
samples primarily from individual clinics or small geo-
graphic areas; to the authors’ knowledge, no study has
been conducted describing the humanistic and economic
burden within a general population survey [5–12]. The
current study estimates the burden of CSU among adults
diagnosed with chronic urticaria in terms of health-related
quality of life (HR-QOL), self-reported depression, anxi-
ety, and sleep difficulties, work and activity impairment,
and healthcare use, using individuals currently using




The present study is a retrospective, cross-sectional analysis
of data taken from the 5EU National Health and Wellness
Survey (NHWS), which is a large cross-sectional survey
designed to reflect health in the general population of France,
Germany, Italy, Spain, and the UK. Potential respondents are
identified primarily through participation in opt-in online
survey panels, with stratified random sampling within the
survey panel to ensure representativeness in terms of age and
sex, and off-panel recruitment is used to ensure representa-
tion of the elderly population using quotas by age and sex.
Previous comparisons have shown NHWS data to be con-
sistentwith that of other health surveysmeant to represent the
general population [13, 14]. The current project incorporates
data from the 5EU surveys conducted in 2010 (N = 57,805),
2011 (N = 57,512), and 2013 (N = 62,000); the 5EU
NHWS was not conducted in 2012. Because the survey is
cross-sectional, and sampling is conducted without regard to
previous participation, some respondents have completed the
survey more than once. The most recent responses were used
for such respondents. Respondents were required to be aged
at least 18 years, able to read and write the primary language
of the country in which the study was conducted, and to
provide informed consent. The protocol andquestionnaire for
theNHWSwas reviewed and approved byEssex Institutional
Review Board (Lebanon, New Jersey, USA).
2.2 Measures
2.2.1 Chronic Spontaneous Urticaria Proxy
Items to identify respondents with CSU in particular were
not included in the NHWS, but the survey respondents
were asked to identify which medical conditions they had
ever experienced from a list that included ‘‘chronic hives
(lasting 6 weeks or more)’’. The term ‘‘hives’’ was used
rather than ‘‘urticaria’’ to ensure the language would be
understood by patients rather than health professionals. No
description of the condition was provided. Those who
indicated experiencing chronic hives were asked to indicate
whether their chronic hives were diagnosed by a doctor,
and whether they were currently using a prescription to
treat their chronic hives. The type of prescription was not
collected. Those who indicated current use of a prescription
were used as the proxy for individuals with CSU (cases) to
ensure both diagnosis of chronic urticaria as well as present
disease at the time of the survey.
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2.2.2 Health-Related Quality of Life
The NHWS assessed HR-QOL using the standard recall
form (4 weeks) of the SF-12v2 for 2010 and 2011 and the
SF-36v2 for the 2013 responses [15, 16]. These are both
generic (i.e., not disease specific) HR-QOL instruments
that allow for comparison across health conditions and can
be used to produce the same metrics for functional health
status. Mental Component Summary (MCS) scores were
used to summarize mental health, and Physical Component
Summary (PCS) scores were used to summarize physical
health. MCS and PCS scores have a mean of 50 and a
standard deviation of 10 for the population. Health utility
scores were also calculated using the SF-6D algorithm,
which provides a preference-based single index measure
for health using UK general population values, with a score
of 1 equivalent to full health [17].
2.2.3 Self-Report of Depression, Anxiety, and Sleep
Problems
Respondents to the survey were asked to indicate which
medical conditions they had experienced in the prior
12 months, one of which was depression. Those who
indicated experience of depression were considered to have
depression. Respondents to the survey were also asked to
indicate whether they have experienced a variety of dif-
ferent types of anxiety in the preceding 12 months,
including anxiety, general anxiety disorder, panic disorder,
phobia, post-traumatic stress, obsessive compulsive disor-
der, and social anxiety disorder. If a respondent indicated
having experienced one or more of these in the past
12 months, they were considered to have anxiety. Like-
wise, respondents who indicated they had experienced
insomnia or sleep difficulties in the prior 12 months were
considered to have sleep difficulties. For all conditions, the
name of the condition was presented to the respondent
without additional description.
2.2.4 Work and Activity Impairment
The Work Productivity and Activity Impairment ques-
tionnaire was included in the study to measure health-re-
lated work and activity impairment [18]. Only respondents
who reported being employed full-time, part-time, or self-
employed provided data for absenteeism (work time mis-
sed due to health), presenteeism (level of health-related
impairment while at work), and overall work impairment
(combined absenteeism and presenteeism). All respondents
provided data for activity impairment (health-related
impairment to non-work activities). All values are reported
as percentages and are based on the 7 days prior to the
survey.
2.2.5 Healthcare Utilization
Healthcare use was defined by visits to different medical
providers during the prior 6 months. These included visits
to specific types of traditional healthcare providers (HCPs:
physicians, nurses, dentists, etc.), which were summed
across types of providers to provide a total. Specific types
of providers who would be expected to provide care for
CSU or the common psychological comorbidities were also
considered individually, including general practitioners
(GPs), allergists, dermatologists, psychiatrists, and psy-
chologists. Respondents also provided the number of
emergency room visits and hospitalizations. Whether the
respondent made at least one visit to various types of
alternative HCPs (herbalists, acupuncturists, chiropractors,
nutritionists, massage therapists, and homeopaths) was also
included in the survey, though the number of such visits
was not asked.
2.2.6 Demographic and Clinical Characteristics
A series of demographic and clinical characteristics were
also included to characterize the sample and serve as
covariates in the regression models. Age, sex, country of
residence, marital status, level of household income, and
employment status were included as demographic mea-
sures. General health characteristics included body mass
index (BMI) calculated from reported height and weight,
cigarette smoking, frequency of alcohol use, and days of
exercise in past month. The Charlson comorbidity index
(CCI) was also calculated from self-reported physician
diagnoses of different conditions to represent the level of
comorbidity among respondents [19]. The greater the total
index score, the greater the comorbid burden on the patient.
2.3 Analysis
Point prevalence of CSU among adults in the 5EU was
estimated using the three possible definitions available in
the NHWS (ever experienced, diagnosed by a physician,
and currently using a prescription) by applying Horvitz-
Thompson weights to respondents according to country,
sex, and age as reported for each country in the interna-
tional database of the US Census in 2013 [20, 21].
In order to quantify burden, cases were matched to 5EU
NHWS respondents who had not experienced chronic
urticaria (controls) in a 1:4 ratio. The matching was ran-
dom without replacement among those sharing the same
country, sex, age (exact), and year of survey. Comparisons
between cases and matched controls were conducted using
chi-squared tests of categorical variables and t-tests for
continuous and count variables. Generalized linear models
were also conducted to adjust for potential confounders.
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These models took into account cigarette smoking, BMI
category, and CCI score, which differed between cases and
controls after matching. Models were selected based on the
distribution of the outcomes. As the distribution of HR-
QOL metrics was roughly normal, linear models were used
for these outcomes. Logistic regression was used for
depression, anxiety, and sleep difficulties, as these were
binary outcomes. Negative binomial models with a log link
function were used for all other outcomes, as the distri-
butions were positively skewed and also were over-dis-
persed for the Poisson distribution.1 To ease interpretation
of the regression models, regression-estimated means are
presented at the mean value of the covariates. Additional
detail for the regression results, such as significance tests
and coefficients for the covariates, odds ratios, and rate
ratios, are presented in the Electronic Supplementary
Material (ESM) 1.
3 Results
There were 175,923 unique respondents across the 3 years
of survey data. The prevalence of chronic urticaria cur-
rently treated with a prescription was estimated at 0.23 %
of the adult population after weighting, with an additional
0.28 % reporting a physician diagnosis, for a prevalence of
0.51 % for diagnosed chronic urticaria. A further 0.12 %
reported having experienced chronic urticaria but not
having received a diagnosis, for a total prevalence of
0.63 % when considering both diagnosed and undiagnosed
cases. The condition was almost twice as common among
women as among men, regardless of definition used
(Table 1).
Bivariate comparisons between cases (n = 369) and
matched controls (n = 1476) indicated that those currently
treated for chronic urticaria (cases) were not significantly
different from controls in terms of household income,
marital status, level of education, frequency of exercise, or
alcohol use (all p[ 0.10). Cases were less likely to be
employed (51.5 vs. 58.6 %, p\ 0.05), had higher mean
BMI (26.6 vs. 25.5, p\ 0.01), and differed in the distri-
bution of BMI and smoking categories (both p\ 0.01),
which was due to a higher proportion of cases being obese
(23.0 vs. 15.9 %) and currently smoking cigarettes (35.5
vs. 28.2 %) than controls. CCI scores were notably higher
among those treated for chronic urticaria than among the
controls (1.7 vs. 0.3, p\ 0.001; Table 2).
All health outcomes were considerably worse among
cases than among matched control respondents. HR-QOL
was significantly worse among those currently treated for
chronic urticaria than among those who had never experi-
enced chronic urticaria (Fig. 1a), including mean MCS
scores (39.6 vs. 45.5), PCS scores (43.4 vs. 50.2), and SF-
6D health utility scores (0.62 vs. 0.71; all p\ 0.001).
Substantial decrements in HR-QOL outcomes remained
among those currently treated for chronic urticaria after
adjusting for BMI category, CCI, and smoking, with the
adjusted mean scores for cases approximately 5 points
lower on both MCS (40.2 vs. 45.4, p\ 0.001) and PCS
(44.6 vs. 49.9) scores (p\ 0.001). Health utility scores
were 0.08 points lower after adjustment (0.63 vs. 0.71,
p\ 0.001) (Fig. 1b).
There was also an association between current treatment
for chronic urticaria and psychological complaints
(Table 3). Self-reported depression was approximately
twice as prevalent among cases than among controls (32.8
vs. 14.6 %, p\ 0.001). Anxiety was experienced by
approximately half of cases, again approximately double
the rate among controls (50.9 vs. 22.6 %, p\ 0.001), and
sleep difficulties were also more common in this group
than among controls (58.0 vs. 32.7 %, p\ 0.001). The
difference in prevalence of these complaints after adjust-
ment for confounders, was similar to the unadjusted fig-
ures. The estimated probability of depression was 27.5 vs.
14.7 % for cases and controls, respectively, and the
prevalence of anxiety was 47.0 % for cases and 23.3 % for
controls (both p\ 0.001). The adjusted prevalence of sleep
difficulties was also higher among cases than controls (54
vs. 34 %, p\ 0.001; Table 3).
Impairment in work and activities is summarized in
Table 4. Average levels of absenteeism (13.4 vs. 5.6 %,
p\ 0.001), presenteeism (33.5 vs. 16.6 %, p\ 0.0001),
Table 1 Prevalence of chronic
urticaria in the 5EU (France,
Germany, Italy, Spain, and UK)
Chronic urticaria Overall Male Female
Ever experienced 0.63 (0.59–0.67) 0.46 (0.41–0.51) 0.79 (0.72–0.85)
Ever diagnosed 0.51 (0.48–0.55) 0.34 (0.30–0.38) 0.67 (0.62–0.73)
Currently treated 0.23 (0.20–0.25) 0.18 (0.14–0.21) 0.28 (0.24–0.31)
Data are presented as % (95 % confidence interval)
Currently treated respondents are a subset of ever-diagnosed respondents, which is a subset of those who
ever experienced chronic urticaria
1 A series of generalized linear mixed models accounting for the
matched structure of the data was also conducted, and resulted in
similar conclusions; these results are available from the correspond-
ing author. Because of the similarity in findings and an issue with
non-convergence for a few outcomes, only the results of the
generalized linear models are presented here.
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and overall work impairment (39.7 vs. 20.1 %, p\ 0.001)
among employed cases were almost double those reported
by employed matched respondents who had never experi-
enced chronic urticaria. Impairment in non-work activities
was also nearly doubled among cases relative to controls
(45.5 vs. 25.1 %, p\ 0.001). Regression adjustment did
little to alter the pattern of results, though the difference in
absenteeism was no longer significant (11.9 vs. 5.3 %,
p = 0.058). Adjusted comparisons for presenteeism (30.5
vs. 16.9 %), overall work impairment (36.6 vs. 20.3 %),
and impairment in non-work activities (42.2 vs. 25.5 %) all
indicated greater impairment among cases than controls
(all p\ 0.01).
Higher levels of healthcare use among cases were also
reported by proxy CSU cases (Table 5). Those currently
treated for chronic urticaria had approximately six more
total HCP visits on average during the 6-month recall
period (11.5 vs. 4.8, p\ 0.001). Analysis of visits to
specific healthcare providers revealed that cases made
more visits to dermatologists, allergists, psychiatrists, and
psychologists (all p\ 0.05). Cases also had notably more
emergency visits (1.1 vs. 0.3, p\ 0.001) and
Table 2 Patient characteristics
in respondents currently treated








Age, mean (SD) 44.4 (15.2) 44.4 (15.2) 1.000
Male 512 (34.7) 128 (34.7) 1.000
Country 1.000
France 356 (24.1) 89 (24.1)
Germany 252 (17.1) 63 (17.1)
UK 276 (18.7) 69 (18.7)
Italy 320 (21.7) 80 (21.7)
Spain 272 (18.4) 68 (18.4)
Employed 865 (58.6) 190 (51.5) 0.014
Household income 0.125
Below median 734 (49.7) 202 (54.7)
Above median 523 (35.4) 125 (33.9)
Declined to answer 219 (14.8) 42 (11.4)
Married/living w/partner 913 (61.9) 224 (60.7) 0.684
Completed university 603 (40.9) 140 (37.9) 0.307
BMI, mean (SD) (n = 1433 [362]) 25.53 (5.15) 26.64 (6.60) 0.003*
Exercise (days in past month) 6.37 (8.21) 6.11 (7.81) 0.572
CCI, mean (SD) 0.29 (0.77) 1.72 (5.02) \0.001*
BMI categories 0.009
Underweight 50 (3.4) 16 (4.3)
Normal 707 (47.9) 152 (41.2)
Overweight 442 (29.9) 109 (29.5)
Obese 234 (15.9) 85 (23.0)
Declined to answer 43 (2.9) 7 (1.9)
Smoking status 0.009
Current 416 (28.2) 131 (35.5)
Former 460 (31.2) 115 (31.2)
Never 600 (40.7) 123 (33.3)
Alcohol use 0.276
Daily 101 (6.8) 32 (8.7)
Less than daily 972 (65.9) 248 (67.2)
None 403 (27.3) 89 (24.1)
Data are presented as n (%) unless otherwise indicated
BMI body mass index, CCI Charlson comorbidity index, SD standard deviation
* p value adjusted for violation of homogeneity of variance assumption
Impact of Chronic Urticaria 555
hospitalizations (0.7 vs. 0.2, p\ 0.001) than controls. The
pattern of more visits among cases than controls was also
seen in the regression results (Table 5). The number of
physician visits was approximately twice as high for those
currently treated for chronic urticaria relative to controls
(9.1 vs. 4.9, p\ 0.001). The pattern was fairly consistent
across types of providers, including GPs, allergists, der-
matologists, and psychiatrists (all p\ 0.05), though psy-
chotherapist visits were not significantly different after
adjustment (p = 0.11). The disparity between cases and
controls in ER visits and hospitalizations was smaller after

































Fig. 1 Health-related quality of life among those currently treated for
chronic urticaria relative to controls. a and b present matched
comparisons before and after regression adjustment, respectively.
Variables used in matching were year of survey, country, age, and
sex. Covariates included cigarette smoking, body mass index
category, and Charlson comorbidity index score. Error bars indicate
standard error of the mean. All comparisons p\ 0.001. MCS Mental
Component Summary, PCS Physical Component Summary
Table 3 Depression, anxiety, and sleep difficulties among respondents currently treated for chronic urticaria and matched controls
Matched comparisons Regression estimates
Control
(N = 1476)
Currently treated for chronic
urticaria (N = 369)
p value Control
(N = 1476)
Currently treated for chronic
urticaria (N = 369)
p value
Depression 216 (14.6) 121 (32.8) \0.001 14.7 (12.9–16.7) 27.5 (23.0–32.5) \0.001
Anxiety 333 (22.6) 188 (50.9) \0.001 23.3 (21.1–25.6) 47.0 (41.7–52.4) \0.001
Sleep difficulties 483 (32.7) 214 (58.0) \0.001 34.2 (31.7–36.8) 54.3 (48.9–59.6) \0.001
Data are presented as n (%) or % (95 % confidence interval)
Variables used in matching were year of survey, country, age, and sex. Covariates included cigarette smoking, BMI category, and CCI score
BMI body mass index, CCI Charlson comorbidity index
Table 4 Impairment in work productivity and non-work activities in respondents currently treated for chronic urticaria and matched controls
Matched comparisons Regression estimates
Control
(N = 1476)
Currently treated for chronic
urticaria (N = 369)
p value Control
(N = 1476)
Currently treated for chronic
urticaria (N = 369)
p value
Work impairment
Absenteeism 5.6 (18.6) 13.4 (26.5) \0.001 5.3 (3.8–7.4) 11.9 (5.6–25.3) 0.058
Presenteeism 16.6 (22.8) 33.5 (29.9) \0.001* 16.9 (14.5–19.6) 30.5 (22.0–42.3) 0.001
Overall 20.1 (27.5) 39.7 (33.8) \0.001 20.3 (17.5–23.5) 36.6 (26.7–50.2) 0.001
Activity impairment 25.1 (28.1) 45.5 (30.8) \0.001* 25.5 (23.3–27.8) 42.2 (35.2–50.5) \0.001
Data are presented as mean % (standard deviation) or mean % (95 % confidence interval)
Variables used in matching were year of survey, country, age, and sex. Covariates included cigarette smoking, BMI category, and CCI score
BMI body mass index, CCI Charlson comorbidity index, SD standard deviation
* p value adjusted for violation of homogeneity of variance assumption
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4 Discussion
The current study suggests that individuals in Europe
currently treated for chronic urticaria have substantially
worse outcomes than those without chronic urticaria across
a variety of domains. This was true both in the comparisons
matching for country, age, sex, and year of survey, as well
as in regressions adjusting for BMI, smoking, and comor-
bidities within the matched samples. Differences in HR-
QOL exceeded commonly accepted 3-point minimally
important differences for MCS and PCS scores; likewise,
the 0.08-point decrement in SF-6D far exceeded the 0.03
threshold used for that measure [16, 22, 23]. Depression,
anxiety, and sleep difficulties were also associated with
current treatment for chronic urticaria. Health-related
impairments in work and non-work activities and health-
care resource use were likewise greater among those with
chronic urticaria than among controls.
It is important to consider that the cases in the current
study reported current use of a prescription for chronic
urticaria rather than CSU per se; the NHWS questionnaires
in 2010–2013 did not include any items to differentiate
between the types of chronic urticaria. Therefore, the
burden quantified here may differ somewhat from that
experienced by patients with confirmed diagnoses of CSU.
However, as CSU is the most common type of chronic
urticaria [5], many of the individuals with chronic urticaria
in this cohort most likely have CSU, suggesting that this
limitation is relatively minor. Though currently treated
patients may be expected to have higher burden, which
leads them to seek treatment, exploratory analyses com-
paring individuals who have either experienced chronic
urticaria or been diagnosed with chronic urticaria also
indicate substantial burden and are not limited to the proxy
definition of the group reported upon here (ESM 2).
The findings should be considered in light of the limi-
tations of the methodology. The survey is subject to
potential biases arising from self-report, such as recall
biases, but these biases would be expected to influence
responses equally across analysis groups. Although the
NHWS is representative of the included countries’ adult
populations in terms of age and sex, the panel-based
recruitment may introduce potential bias for variables that
are not incorporated in the sampling strata, such as edu-
cation. Because both cases and controls were drawn from
the same panel, this limitation would also be expected to
have little impact on the estimated burden of the condition,
though it could have affected the proportion of respondents
with chronic urticaria. Likewise, because no description
was provided for ‘‘chronic hives,’’ some respondents
experiencing the condition but unfamiliar with the term
may not have been identified in the survey, which may
have affected the prevalence estimate for undiagnosed
patients. The SF-36v2, used in the NHWS to assess HR-
QOL, is a generic instrument that allows measurement of
health status in any disease as well as in individuals free of
disease. While this allows the health status of these patients
to be compared with that of individuals without urticaria or
other dermatological conditions, a more specific HR-QOL
instrument would provide additional information and
potentially a fuller description of the burden of the condi-
tion. As indicated earlier, all measures were self-report,
which provides the patient perspective though is also
potentially subject to bias. Measures also included different
recall periods, ranging from 1 week for work and activity
impairment to 1 year for anxiety, depression, and sleep
Table 5 Number of all-cause healthcare visits during the prior 6 months among respondents currently treated for chronic urticaria and matched
controls
Type of provider Matched comparisons Regression estimates
Control
(N = 1476)
Currently treated for chronic
urticaria (N = 369)
p value Control
(N = 1476)
Currently treated for chronic
urticaria (N = 369)
p value
Physician 4.82 (6.77) 11.47 (18.81) \0.001 4.87 (4.61–5.15) 9.06 (8.15–10.09) \0.001
GP 1.87 (2.54) 3.73 (5.05) \0.001 1.88 (1.76–2.00) 3.52 (3.13–3.96) \0.001
Allergist 0.04 (0.33) 0.34 (0.89) \0.001 0.04 (0.03–0.05) 0.30 (0.21–0.41) \0.001
Dermatologist 0.11 (0.57) 0.56 (1.31) \0.001* 0.11 (0.09–0.13) 0.50 (0.38–0.66) \0.001
Psychotherapist 0.17 (1.39) 0.42 (2.13) 0.033* 0.11 (0.07–0.17) 0.24 (0.10–0.56) 0.107
Psychiatrist 0.16 (1.49) 0.41 (1.72) 0.010* 0.14 (0.09–0.20) 0.39 (0.18–0.85) 0.023
ER 0.30 (2.00) 1.12 (3.35) \0.001 0.28 (0.24–0.33) 0.75 (0.57–0.99) \0.001
Hospital 0.18 (1.34) 0.66 (2.45) \0.001* 0.16 (0.13–0.20) 0.33 (0.22–0.49) 0.002
Data are presented as mean (standard deviation) or mean (95 % confidence interval)
Variables used in matching were year of survey, country, age, and sex. Covariates included cigarette smoking, BMI category, and CCI score
BMI body mass index, CCI Charlson comorbidity index, ER emergency room, GP general practitioner, RR rate ratio
*p value adjusted for violation of homogeneity of variance assumption
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difficulties. Healthcare use, which used a 6-month recall
period, and psychological complaints, which were recalled
over the prior 12 months, may not have coincided with
treatment for chronic urticaria for some of the patients.
Finally, though measured confounders were either used as
matching variables or adjusted for in the regressions, there
may have been unmeasured confounders that may account
for some portion of the differences in health outcomes
between cases and controls (e.g., family history of mental
illness), and the cross-sectional design of the study does
allow us to differentiate between the causes and conse-
quences of chronic urticaria.
5 Conclusions
Despite the above limitations, the results of the current
study using the proxy definition of chronic urticaria cur-
rently treated with a prescription suggest that CSU imposes
a substantial burden on patient well-being and ability to be
productive at work and in activities outside of work and is
associated with more healthcare use. Depression, anxiety,
and sleep difficulties were also notably more common
among those currently treated for chronic urticaria.
Research incorporating respondents with a confirmed
diagnosis of CSU is needed to confirm these findings.
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